JFG
DMAC icon

Jefferies Financial Group’s DiaMedica Therapeutics DMAC Stock Holding History

Jefferies Financial Group’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-26,000
Closed -$98.5K – 1418
2025
Q1 		$98.5K Hold
26,000
– – ﹤0.01% 1469
2024
Q4 		$141K Hold
26,000
– – ﹤0.01% 1431
2024
Q3 		$109K Buy
+26,000
New +$96K ﹤0.01% 1281

Other funds holding DMAC

CLG
Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jefferies Financial Group's DMAC Position: Q2 2025 in Review

Jefferies Financial Group sold out of DiaMedica Therapeutics (DMAC) in Q2 2025, closing a stake of 26,000 shares — an estimated $98.5K sold.

Jefferies Financial Group first reported a position in DMAC in Q3 2024 and held it in 3 quarters. The position peaked at $141K in Q4 2024. 58 funds tracked by Wall St. Rank hold DMAC as of Q2 2025.

  • Jefferies Financial Group reported no remaining DiaMedica Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Jefferies Financial Group sold 26,000 DiaMedica Therapeutics shares in Q2 2025, an estimated $98.5K.
  • Jefferies Financial Group first reported a position in DiaMedica Therapeutics in Q3 2024 and held it in 3 quarters.
  • Jefferies Financial Group's DiaMedica Therapeutics position peaked at $141K in Q4 2024.
  • 58 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2025.

Based on Jefferies Financial Group's 13F filing for Q2 2025, filed 12 Aug 2025.